The global macular degeneration treatment market is poised for significant growth, projected to expand from USD 9.1 billion ...

Outlook Therapeutics OTLK reported preliminary top-line results from the 90-day non-inferiority NORSE EIGHT clinical study ...

Outlook said it remains confident that ONS-5010, marketed as Lytenava in the EU, is an important therapy for the treatment of wet age-related macular degeneration in place of off-label repackaged ...

Post hoc analyses of the AREDS / AREDS2 studies presented at the recent American Academy of Ophthalmology meeting examined ...

Outlook Therapeutics (OTLK) stock plunges 81% after clinical trial failure for its wet AMD therapy, ONS-5010. Read more here.

At Beilinson Hospital, we are committed to tackling this issue head-on by embracing the technological revolution in eye care.

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA ...

Findings from a post hoc analysis of the AREDS and AREDS2 studies were presented at the recent American Academy of ...

Lorati Company Limited has introduced a groundbreaking advancement in the treatment of age-related macular degeneration (AMD), including both dry and wet forms, with its nano-grade eye drops. Mr.

Dublin, Nov. 22, 2024 (GLOBE NEWSWIRE) -- The "Wet Age-Related Macular Degeneration (Wet AMD) - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. The emergent ...

Final efficacy data expected in January 2025Anticipate resubmission of BLA in calendar Q1 2025ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- ...